Profound Medical (TSE:PRN) Insider Richard Ringler Fabian Buys 10,000 Shares

Profound Medical Corp. (TSE:PRN) insider Richard Ringler Fabian acquired 10,000 shares of the business’s stock in a transaction on Thursday, September 17th. The shares were purchased at an average price of C$8.31 per share, with a total value of C$83,100.00. Following the transaction, the insider owned 10,000 shares in the company, valued at C$83,100. The trade was a ∞ increase in their position.

Profound Medical Stock Up 0.6%

Shares of TSE:PRN opened at C$8.23 on Friday. The company has a market cap of C$300.72 million, a price-to-earnings ratio of -8.31 and a beta of 1.06. The firm’s 50-day simple moving average is C$9.65 and its 200-day simple moving average is C$9.30. The company has a quick ratio of 14.98, a current ratio of 6.46 and a debt-to-equity ratio of 14.82. Profound Medical Corp. has a fifty-two week low of C$5.36 and a fifty-two week high of C$12.40.

Profound Medical (TSE:PRN) last posted its quarterly earnings results on Thursday, August 6th. The company reported C($0.37) earnings per share (EPS) for the quarter. The firm had revenue of C$3.53 million for the quarter. Profound Medical had a negative return on equity of 62.45% and a negative net margin of 170.92%. As a group, equities research analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Raymond James Financial raised Profound Medical from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, July 27th. Five equities research analysts have rated the stock with a Buy rating, nineteen have assigned a Moderate Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Profound Medical presently has an average rating of “Moderate Buy” and an average target price of C$8.23.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.